One in 13 Australians over the age of 40 has chronic obstructive pulmonary disease or COPD but, alarmingly, only half of them ...

糖皮质激素（GC）的药理作用及临床适应症广泛，因其强大的抗炎、平喘作用，在呼吸科常被用于 慢性阻塞性肺疾病 （ COPD ）、 哮喘 等疾病治疗。GC 可缓解患者的临床症状、改善肺功能，提高生活质量。

Respiratory Inhaler Devices MarketThe global respiratory inhaler devices market, valued at USD 37,258.5 million in 2023, is projected to grow at a compound annual growth rate (CAGR) of 4.90%, reaching ...

These compelling results support advancing the development of nintedanib DPI for patients living with IPF, a chronic and progressive fibrotic lung disease with limited treatment options,” said Michael ...

Chronic obstructive pulmonary disease is a serious, progressive illness that hits the homeless and underinsured the hardest.

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Labels of all GLP-1 receptor agonists now carry ...

Alexander Mathioudakis, MD, PhD, clinical lecturer in respiratory medicine at The University of Manchester, discusses insights from the FLAME trial analysis and the ICS-RECODE meta-analysis.

About MannKind MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for ...

Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration ...

Therapies that target the prostacyclin pathway hold promise as chronic CTEPH treatment, a meta-analysis of controlled trials ...

Cambridge Healthcare Innovations (CHI) has joined forces with Aptar Pharma in the US to commercialise the Science Park ...

CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for the treatment of life-threatening ...